[go: up one dir, main page]

MEP34108A - Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere - Google Patents

Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere

Info

Publication number
MEP34108A
MEP34108A MEP-341/08A MEP34108A MEP34108A ME P34108 A MEP34108 A ME P34108A ME P34108 A MEP34108 A ME P34108A ME P34108 A MEP34108 A ME P34108A
Authority
ME
Montenegro
Prior art keywords
extended
controlled release
pharmaceutical compositions
containing electrical
release
Prior art date
Application number
MEP-341/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/278,912 external-priority patent/US20030114394A1/en
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MEP34108A publication Critical patent/MEP34108A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-341/08A 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere MEP34108A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/278,912 US20030114394A1 (en) 2001-10-29 2002-10-24 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US43850103P 2003-01-08 2003-01-08
PCT/EP2003/004316 WO2004037229A1 (en) 2002-10-24 2003-04-25 Extended, controlled release pharmaceutical compositions comprising charged polymers

Publications (1)

Publication Number Publication Date
MEP34108A true MEP34108A (hr) 2011-02-10

Family

ID=32179474

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-341/08A MEP34108A (hr) 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere
MEP-2008-341A ME00233B (me) 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-341A ME00233B (me) 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere

Country Status (23)

Country Link
EP (1) EP1556015B1 (xx)
JP (1) JP5204374B2 (xx)
KR (1) KR20050083802A (xx)
CN (2) CN101327326A (xx)
AR (1) AR039464A1 (xx)
AU (1) AU2003233066B2 (xx)
BR (1) BR0315576A (xx)
CA (1) CA2503383C (xx)
CO (1) CO5700711A2 (xx)
ES (1) ES2618300T3 (xx)
HR (1) HRP20050448A2 (xx)
MA (1) MA27493A1 (xx)
ME (2) MEP34108A (xx)
MX (1) MXPA05004330A (xx)
NO (1) NO20052480L (xx)
NZ (1) NZ539512A (xx)
PE (2) PE20040323A1 (xx)
PL (1) PL376537A1 (xx)
RS (1) RS20050321A (xx)
RU (2) RU2366410C2 (xx)
TW (1) TW200406223A (xx)
WO (1) WO2004037229A1 (xx)
ZA (1) ZA200503133B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101170997A (zh) * 2005-05-10 2008-04-30 诺瓦提斯公司 改进释放的泛昔洛韦药物组合物
WO2017130208A1 (en) * 2016-01-29 2017-08-03 Faheem Hyder Pottoo Triple drug combination for treatment of status epilepticus and/or partial seizures and/or partial seizures with associated neurological disorders
CN119074731A (zh) * 2024-09-20 2024-12-06 湖南师范大学 盐酸达克罗宁在预防雌性小鼠下丘脑-垂体-卵巢轴损伤中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
DK0431719T3 (da) * 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
IL114589A (en) * 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
IL128774A (en) * 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу

Also Published As

Publication number Publication date
AU2003233066A1 (en) 2004-05-13
CA2503383A1 (en) 2004-05-06
WO2004037229A1 (en) 2004-05-06
PL376537A1 (pl) 2006-01-09
CN101327326A (zh) 2008-12-24
NO20052480L (no) 2005-07-25
EP1556015B1 (en) 2017-02-22
MXPA05004330A (es) 2005-08-02
RU2005115574A (ru) 2005-10-27
CN1703205B (zh) 2010-12-01
ES2618300T3 (es) 2017-06-21
BR0315576A (pt) 2005-08-30
CN1703205A (zh) 2005-11-30
RU2009112072A (ru) 2010-10-10
NO20052480D0 (no) 2005-05-23
AR039464A1 (es) 2005-02-23
PE20040323A1 (es) 2004-06-10
KR20050083802A (ko) 2005-08-26
MA27493A1 (fr) 2005-08-01
TW200406223A (en) 2004-05-01
HRP20050448A2 (en) 2005-12-31
RS20050321A (sr) 2007-08-03
JP5204374B2 (ja) 2013-06-05
PE20081613A1 (es) 2008-11-15
AU2003233066B2 (en) 2009-11-19
ZA200503133B (en) 2006-12-27
CA2503383C (en) 2013-03-12
RU2366410C2 (ru) 2009-09-10
JP2006506453A (ja) 2006-02-23
NZ539512A (en) 2009-03-31
ME00233B (me) 2011-05-10
EP1556015A1 (en) 2005-07-27
CO5700711A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
DK1162943T3 (da) Ikke-sviende coatingpræparat
BRPI0509366A (pt) método para remover potássio de um indivìduo animal, formulação farmacêutica, métodos para tratar uma doença e para determinar uma permeabilidade de casca a um ìon, composição farmacêutica, composição de núcleo-casca,e, método para sintetizar um polìmero de alfa-fluroacrilato
CY1119660T1 (el) Antibakthpiakh απο toy στοματος συνθεση
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
ATE289332T1 (de) Silikongel enthaltend salizylsäure
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BRPI0416032A (pt) excipientes em veìculos de distribuição de fármacos
DE602004006165D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
BRPI0518187A (pt) formulações de olanzapina em nanopartìcula injetáveis
WO2008089151A3 (en) High dose film compositions and methods of preparation
WO2005009357A3 (en) Controlled release compositions
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
DK1047409T3 (da) TTS indeholdende en antioxidant
EP2485720A4 (en) LOW-ETHER COMPOSITION AND ADMINISTRATION APPARATUS
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
TW200733980A (en) Phase transitive breath care products
MEP34108A (hr) Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere
CY1120920T1 (el) Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
AU2003256882A8 (en) Methods of drug delivery using sulphated chitinous polymers
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES